200
Participants
Start Date
July 1, 2025
Primary Completion Date
July 1, 2027
Study Completion Date
July 1, 2027
Innovative Device Group
Catheter-based thrombectomy is performed within 4 hours after baseline CTPA acquisition. Pre-procedural anticoagulation with either low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) is administered prior to thrombectomy. Post-procedural oral anticoagulation is transitioned to rivaroxaban 20 mg once daily (QD).
Standard Pharmacological Therapy Group
Following thrombolytic agent administration, anticoagulation with rivaroxaban is initiated and maintained at 15 mg twice daily (BID) for the initial 3 weeks, then switched to 20 mg once daily (QD) thereafter.
RenJi Hospital
OTHER